Shandong Luning Pharmaceutical Co., Ltd.

Main purpose: To observe the time course of blood drug concentration after a single oral dose of the test preparation lipoic acid tablets (specification: 0.6g, license holder: Shandong Luning Pharmaceutical Co., Ltd.) in healthy subjects in the fasting state, estimate the corresponding pharmacokinetic parameters, and use lipoic acid tablets (trade name: Thioctacid® 600HR, specification: 0.6g, license holder: MEDA Pharma GmbH & Co. KG) as the reference preparation to conduct a formal human bioequivalence test to provide a reference for the registration and clinical application of the drug. Secondary purpose: To observe the safety of the test preparation and reference preparation when the subjects take them orally in the fasting state.

1) Primary objective: To evaluate the bioequivalence of the test formulation (Empagliflozin tablets produced by Shandong Luning Pharmaceutical Co., Ltd., specification: 25 mg) and the reference formulation (Empagliflozin tablets certified by Boehringer Ingelheim International GmbH, specification: 25 mg; trade name: Jardiance®) in Chinese healthy subjects under fasting and fed conditions, using the main pharmacokinetic parameters (AUC and Cmax) of Empagliflozin as bioequivalence evaluation indicators. 2) Secondary objective: To observe the safety of the test formulation and the reference formulation under fasting and fed conditions.

①Evaluate the safety, tolerability and pharmacokinetic (PK) characteristics of LN020 dry suspension after a single dose in healthy Chinese subjects; ②Compare the PK characteristics and safety of LN020 dry suspension and mabaloxavir tablets in healthy Chinese subjects; ③Evaluate the effect of food on the PK characteristics of LN020 dry suspension in healthy Chinese subjects.